Acquisition of 60% stake in Prathyak Laboratories R&D facility completed for Rs. 15 crore

Sai Parenterals has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited, an operating R&D centre at Genome Valley, Hyderabad, for Rs. 15 crore.

Mon 5 Oct 2026

Stake Acquired

60% equity stake in Prathyak Laboratories Private Limited

Consideration

Rs. 15 crore

Funding Source

unutilised net proceeds of its initial public offering

Acquired R&D Centre Team & Pipeline

28 research scientists and a pipeline of 150 SKUs across 86 molecules

Residual Stake Option

residual 40% may be acquired through a Right of First Refusal at the same valuation

An R&D centre bought rather than built

• Sai Parenterals Limited has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited, an operating research and development centre at Genome Valley, Hyderabad.
• The consideration is Rs. 15 crore, funded from the unutilised net proceeds of the Company's initial public offering.
• Prathyak becomes a direct subsidiary of the Company and has been renamed Sai Prathyak Laboratories Private Limited.

What the acquired centre brings

• Prathyak has been in operation for three years.
• It brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules.
• Its proven capability lies in lyophilised, liposomal and nano-based complex injectables, and in oncology injectables.
• The Company states these are precisely the areas in which it is building its regulated-market injectable franchise.

What it replaces

• The acquisition replaces the greenfield research centre the Company had originally intended to build, for which an allocation had been earmarked in the objects of the issue.
• The Company says acquiring an operating platform rather than constructing one allows development work to begin immediately, removes the construction cycle, and avoids the considerably harder task of assembling a scientific team of this calibre, which it says would have slowed a greenfield build.

How it fits the wider business

• Formulations developed at the centre can be taken into commercial production as the Company's injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets.
• The platform also supports the Group's Australian and New Zealand business, where renewed supply agreements carry a contractual commitment to introduce new products each year.

The remaining stake

• The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction, to be funded from internal accruals, taking Prathyak to a wholly owned position.

What management said

Mr. Anil Kumar Karusala, Chairman and Managing Director, said Prathyak gives the Company 28 research scientists who have worked together for three years and a pipeline of 150 SKUs across 86 molecules in the complex injectable and oncology areas it is building towards. He added that the Company has acquired 60% today and will move to full ownership at the same valuation, that work already completed at the centre can be taken into production as injectable capacity expands, and that the same R&D team will develop new products the Group is required to launch each year under its Australian agreements.

About the Company, as set out in the release

• An integrated, IP-led pharmaceutical enterprise operating across two verticals: contract development and manufacturing for Indian and multinational customers, and branded generic formulations sold domestically and exported into regulated and semi-regulated markets.
• The portfolio spans 302 commercial products across nine therapeutic areas, supported by 599 approved registrations and 67 dossiers under development.
• Manufacturing runs across six facilities, five in India and one in Australia, carrying GMP, WHO-GMP, TGA-Australia and PIC/S accreditations.
• Through Noumed Pharmaceuticals in Australia and New Zealand, acquired in November 2025, the Company holds 15 exclusive long-term supply agreements covering 526 SKUs and a library of over 451 TGA-approved dossiers.
• More than 50% of consolidated revenue is contracted under long-term regulated-market agreements.

The release states that statements about future status, events or circumstances, including plans and objectives, research and development progress, and project potential, are forward-looking and subject to risks and uncertainties.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.